At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 514 enrolled
Drug / intervention
Carvedilol Phosphate modified release formulation +1 moredrug
Likely dose
Not stated in record
Key inclusion· 3
- ✓Documented history of hypertension
- ✓Triglycerides 120–400 mg/dL
- ✓LDL cholesterol levels not requiring lipid-lowering medication
Key exclusion· 4
- ✕Known contraindication to alpha- or beta-blocker therapy
- ✕Prior use of non-ocular beta-blockers within 3 months before screening
- ✕Type I or II diabetes
- ✕Concurrent lipid-lowering medication use
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) With Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients
In Brief
A Phase 3 clinical trial evaluating Carvedilol Phosphate modified release formulation and metoprolol succinate for Hypertension. Completed, enrolled 514 participants across 120 sites in 3 countries.
Detailed Summary
This study was designed to determine whether treatment with COREG MR is more effective at maintaining a better lipid profile than treatment with TOPROL-XL for hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesCanada, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedJan 2006
Primary CompletionDec 2007
Study CompletionDec 2007
TodayJul 2026
First PostedJan 9, 2006
Enrollment StartJan 5, 2006
Primary CompletionDec 1, 2007
Study CompletionDec 28, 2007
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.5 years ago
Interventions
Carvedilol Phosphate modified release formulationdrug
metoprolol succinatedrug